CureVac Delisted Following BioNTech Acquisition Completion
Published on 02/05/2026 at 03:13 | Redaktion boerse-global.de
The chapter for CureVac as an independent publicly traded company has officially closed. The biotech firm’s shares have been removed from the Nasdaq exchange and trading has ceased, marking its full absorption into rival BioNTech. The Tübingen-based company, once a beacon of hope in the sector, has now been integrated into its competitor’s corporate structure.
A complete leadership overhaul accompanied the change in ownership. CureVac’s former executive board resigned en masse. The company’s operations are now directed by BioNTech’s leadership, including CEO Ugur Sahin and COO Sierk Poetting. The primary operational focus is on integration: BioNTech is absorbing CureVac’s research facilities and production capacities in Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
